Skip to content
Search

Latest Stories

UK Covid-19 prevalence up due to Delta not Omicron

The prevalence of Covid-19 infections in England rose to around one in 60 people in the week ending November 27, the Office for National Statistics said today (December 03), led higher by the dominant Delta variant rather than the newly identified Omicron.

The prevalence was up from one in 65 reported the previous week, the ONS said, adding that 99 per cent of all coronavirus infections which were sequenced were genetically compatible with the Delta variant.


"To date, we have not identified any infections compatible with the new Omicron variant (B.1.1.529) among our survey participants," the ONS said.

Prime Minister Boris Johnson has introduced travel restrictions and some mask mandates, with a view to slowing the spread of Omicron while work is undertaken to understand it better.

There have been 42 confirmed cases of the variant in Britain, which has mutations consistent with reduced vaccine efficacy.

But it is the spread of the dominant and highly transmissible Delta variant, especially among children, that is keeping infection levels high. On Thursday, Britain reported its highest daily infection number since July.

The ONS said that infections had increased in younger children, with 4.25 per cent estimated to be infected, and remained high in older children, where 3.46 per cent were estimated to be infected.

Ravi Gupta, professor of clinical microbiology, University of Cambridge, said that it was not a given that Omicron would entirely displace Delta, which might continue to circulate in unvaccinated populations like young children.

"More Delta circulating in kids and then more Omicron circulating proportionately in vaccinated individuals is one scenario that could play out... it will be hard to displace Delta completely," he told Reuters.

"Omicron is not spreading rapidly at the moment, by the look of it... there is probably sustained community transmission, but it's probably just starting."

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less